Mar 27, 2023
Publications
Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
Publication: bioRxiv
Authors: Christian Garde, Michail A Pavlidis, Pablo Garces, Emma J Lange, Sri H Ramarathinam, Mateo Sokac, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J Birkbak, Jens V Kringelum, Birgitte Rono, Anthony W Purcell, Thomas Trolle
Mar 26, 2023
Press releases
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy
This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy
Mar 15, 2023
Press releases
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.
Feb 8, 2023
Press releases
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
Evaxion and Pantherna announced that the tumor neoantigens, identified by Evaxion's PIONEER, demonstrates strong immune response
Jan 19, 2023
Presentations
Redeye Fight Cancer – January 2023
Our CEO, Per Norlén, presented at Redeye Fight Cancer on January 19, 2023.
Jan 3, 2023
Press releases
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
Evaxion today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.
Dec 15, 2022
Press releases
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.
Dec 6, 2022
Press releases
Evaxion and ExpreS2ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate
Evaxion has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech for the joint development of a novel cytomegalovirus (CMV) vaccine candidate
Dec 5, 2022
Presentations
Get to know CEO Per Norlén
Redeye interviewed Evaxion’s newly appointed CEO, Per Norlén, about his background, reasons for joining the company, and hopes for the future
Nov 29, 2022
Presentations
BioStock Life Science Fall Summit 2022
Our CEO, Per Norlén, presented the company at BioStock Life Science Fall Summit 2022 in Lund, Sweden. In the video, you can hear more about how we use the power of our AI to make a unique and personalized treatment for each patient
Nov 17, 2022
Press releases
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.
Nov 16, 2022
Publications
Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions
Publication: Frontiers in Immunology
Authors: Nikolas Hallberg Thuesen, Michael Schantz Klausen, Shyam Gopalakrishnan, Thomas Trolle and Gabriel Renaud
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.